The present study was undertaken to determine the effect of GH administration on GH and IGF-I receptors in skeletal muscle compared with liver in growing pigs. Plasma IGF-I and GH-binding protein (GHBP) levels were also determined. Twelve Large White pigs (castrated males) were treated daily with 100 µg pituitary porcine GH (pGH) per kg body weight or vehicle for 41 days intramusculary. Relative to controls, pGH administration increased plasma IGF-I concentrations by 3·3-fold. Administration of pGH had no effect on plasma GHBP levels. In liver, 125 I-labelled bovine GH (bGH)-specific binding (P<0·05) and GH receptor (GHR) mRNA levels (P<0·05) were higher in pGH-treated than in control pigs. In longissimus dorsi (LD), 125 I-labelled bGH specific binding did not differ significantly between the two groups while GHR mRNA levels (P<0·05) were lower in pGH-treated than in control pigs. Administration of pGH had no effect on 125 I-labelled bGH-specific binding and GHR mRNA levels in trapezius (TR).
Introduction
The growth hormone (GH)-insulin-like growth factor-I (IGF-I) axis plays a major role in growth regulation. Numerous studies in pigs have shown that GH administration markedly increases muscle growth (e.g. Chung et al. 1985 , Campbell et al. 1989 . The mechanisms involved in GH action remain unresolved. Many of the effects of GH are believed to be mediated by IGF-I. Although GH receptor (GHR) is mainly expressed in liver, it is also found in many other tissues including skeletal muscle (Louveau & Etherton 1992) . The concomitant presence of GHR and IGF-I receptors (IGF-IRs) in skeletal muscle suggests that both GH and IGF-I may play a role in muscle growth. The finding that treatment of growing pigs with porcine GH (pGH) increases levels of IGF-I mRNA in liver but not in skeletal muscle (Grant et al. 1991 , Coleman et al. 1994 suggests, at least in pigs, that the effects of GH on skeletal muscle are not due to an increase in local expression of IGF-I. One way to study the respective influence of GH and IGF-I in skeletal muscle is to determine the effects of GH administration on GHR and IGF-IR levels. A number of studies have shown that GH administration leads to an increase in GHR levels in liver (Baxter & Zaltsman 1984 , Chung & Etherton 1986 , Bass et al. 1991 , Ambler et al. 1992 . There are, however, few data on the influence of GH treatment on GHR and IGF-IR in skeletal muscle.
In addition to GHR in tissues, a plasma GH-binding protein (GHBP) has been identified in several species including pigs (Davis et al. 1992) . GHBP may result from proteolytic cleavage of GHR in pigs, as in man and rabbit (Leung et al. 1987) . It has been suggested that plasma GHBP may reflect hepatic GHR levels. The possibility of a co-regulation of GHBP and GHR by GH has been investigated in rodents and pigs, but the results are conflicting. In pGH-treated pigs, a parallel increase in plasma GHBP and hepatic GHR levels was observed (Ambler et al. 1992) . In female rat, hypophysectomy decreases both plasma GHBP and hepatic GH binding (Maiter et al. 1992) . However, continuous infusion of GH leads to an increase in GHBP mRNA abundance with no apparent change in GHR mRNA levels in liver of hypophysectomized animals (Maiter et al. 1992) .
The present experiment was undertaken to determine the influence of GH administration on GHR and IGF-IR in skeletal muscle compared with liver. Plasma IGF-I and GHBP levels were also determined and the possibility of a co-regulation between GHR and GHBP was examined.
Materials and Methods

Animals and sample collection
Six litters of pigs (Large White) were used. Two castrated male pigs (75 1 kg body weight and 137 days of age) from each litter were allotted to one of two groups. They were all fed ad libitum with the same commercial diet providing 13·2 MJ/kg of digestible energy, 17·2% protein and 0·84% lysine and had free access to water. Pigs were treated with pituitary pGH or vehicle (75 m bicarbonate buffer). pGH and vehicle were administered i.m. once a day at a dose of 100 µg/kg body weight. Pigs were weighed weekly to adjust dosage of GH. The final injection on day 41 of treatment was given 24 h before slaughter. Immediately after slaughter, blood, liver, longissimus dorsi (LD, a white muscle) and trapezius (TR, a red muscle) samples were collected. Plasma and tissues for binding studies were stored at 20 C while tissues for mRNA analysis were frozen in liquid nitrogen and stored at 70 C until assayed.
Plasma concentrations of IGF-I
Plasma IGF-I concentrations were determined using a double-antibody RIA after acid-ethanol extraction as described by Daughaday et al. (1980) . The assay was performed using recombinant IGF-I (human recombinant IGF-I, receptor quality; Mallinckrodt, St Louis, MO, USA) as a tracer with a specific activity of 144 µCi/µg and as a standard. A polyclonal antibody raised in rabbit (Claus et al. 1992 ) was used at a final dilution of 1:40 000. All samples were analysed within a single assay. The intraassay coefficient of variation for plasma samples containing 41 and 486 ng/ml of IGF-I were 8·8 and 12·9% respectively. As recommended by Bang et al. (1995) , the assay was validated . Levels of IGF-I determined after an acid-ethanol extraction were compared with levels determined after a glycyl-glycine/G-50 extraction (Frey et al. 1994) . In agreement with previous findings in pigs (Frey et al. 1994) , the present data indicated that, although acid-ethanol extraction led to IGF-I levels that differed from those obtained for glycylglycine/G-50 extracted plasma, there was a close relationship (r=0·97, P<0·001) between the values obtained by these two methods.
Membrane preparation
Microsomal membranes were prepared as previously described (Meserole & Etherton 1984) . In brief, frozen tissues were cut into small pieces and homogenized (1:5, w/v) in ice-cold 50 m Tris-HCl buffer (pH 7·4) containing 250 m sucrose, 1 m EDTA and 1 m phenylmethylsulphonyl fluoride using a Polytron homogenizer (Kinematica, speed 6-7 for 30 s, probe diameters 12 and 20 mm for liver and muscle respectively). After the final centrifugation (100 000 g, 60 min), the pellet was resuspended in 50 m Tris-HCl buffer (pH 7·4), and the microsomal membrane preparations were stored at 20 C until binding studies were performed. Protein concentration was estimated using the bicinchoninic acid assay (Pierce, Rockford, IL, USA) with BSA as standard.
GH-binding assays
All GH-binding assays were carried out in triplicate in the same assay, as previously described (Schnoebelen-Combes et al. 1996) . Briefly, microsomal membrane proteins (400 µg for liver and 500 µg/tube for skeletal muscle) were incubated with 125 I-labelled bGH (30 000 c.p.m./tube or 0·3 ng) in 25 m Tris-HCl (pH 7·4) containing 10 m CaCl 2 , 0·5% BSA and 0·02% NaN 3 (binding buffer) in the absence or presence of an excess of unlabelled bGH. After a 48 h incubation at room temperature, 2 ml ice-cold binding buffer were added to stop the reaction. To test for possible occupancy of GHR by endogenous pGH, hepatic microsomal membranes from each group were treated with 4  MgCl 2 (Kelly et al. 1979 ). Because no difference in 125 I-labelled bGH binding was observed between treated and untreated membranes, MgCl 2 treatment was not used in the present study.
IGF-I-binding assays
IGF-I-binding studies were carried out in triplicate in the same assay, as previously described . Briefly, microsomal membrane proteins (400 µg for liver and 500 µg/tube for skeletal muscle) were incubated in 50 m Tris-HCl (pH 7·4) containing 5 m MgCl 2 , 0·5% BSA and 0·02% NaN 3 (binding buffer) at 4 C for 20-24 h with 125 I-labelled IGF-I (60 000 c.p.m., 0·2 ng) in the absence or presence of unlabelled porcine insulin to determine specific binding. The assay was stopped by adding 2 ml ice-cold binding buffer.
GHBP determinations
Human GH (hGH; Serono Laboratories, Geneva, Switzerland) was iodinated to a specific activity of 100-150 µCi/µg. This radioligand was used because specific binding to porcine GHBP was higher than with pGH (Davis et al. 1992) . GHBP level was determined using HPLC gel filtration as previously described by Tar et al. (1990) . After filtration through a 0·45 µm Millipore (Bedford, MA, USA) minifilter, plasma (100 µl) was incubated overnight at 4 C with 100 µl buffer (0·1  KH 2 PO 4 (pH 7·0), 0·1% BSA) containing 125 I-labelled hGH (100 000 c.p.m./tube or 2 ng/ml) in the absence or presence of an excess of unlabelled hGH to determine specific binding. The entire incubation mixture was placed on to a HPLC Protein Pak 300 sw column (Waters; 0·75 30 cm; Milford, MA, USA). Elution was performed using a degassed buffer (0·1  Na 2 SO 4 , 0·1  KH 2 PO 4 , pH 7·0). To ensure that endogenous GH did not interfere with GHBP measurement, plasma pGH concentrations were determined using double-antibody RIA . Plasma GH concentrations ranged between 1·8 and 5·3 ng/ml and 4·3 and 11·8 ng/ml for control and pGH-treated pigs respectively. Preliminary experiments indicated (data not shown) that a significant reduction in specific binding of 125 I-labelled hGH was observed at concentrations of pGH exceeding 25 ng/ml. The concentration of GH in the plasma of pGH-treated pigs was too low to cause appreciable interference with GHBP measurements. Thus no correction was made for the estimation of GHBP levels.
RNA isolation and RNase protection assays
Total RNA were isolated from tissues using the guanidinium thiocyanate method (Chomczynski & Sacchi 1987) . Quantity and quality of total RNA were evaluated spectrophotometrically and confirmed by horizontal gel electrophoresis. The abundance of GHR and IGF-IR mRNA was quantified using a sensitive solution hybridization-RNase protection assay. Assays were carried out in triplicate on total RNA. Aliquots used for GHR and IGF-IR mRNA analysis were prepared at the same time.
Porcine GHR cDNA in pGEM 3zf-plasmid (Promega, Madison, WI, USA) was kindly provided by Dr T D Etherton (Penn State University, PA, USA). Porcine IGF-IR cDNA, subcloned into pBS M13+ plasmid (Stratagene, La Jolla, CA, USA), was a gift from Dr R J Urban (University of Texas Medical Branch, TX, USA). To generate antisense riboprobes, GHR and IGF-IR plasmids were linearized using HindII and BamHI respectively (Boehringer, Meylan, France). They were transcribed with a riboprobe in vitro transcription system using T7 and T3 polymerase (Promega) for GHR and IGF-IR respectively, in the presence of [ -32 P]CTP (Du Pont de Nemours, Les Ulis, France). The 32 P-labelled GHR riboprobe consisted of 375 nucleotides, of which 368 were the complementary sequence +654 to +1021 of the GHR. The 32 P-labelled IGF-IR riboprobe consisted of 615 nucleotides, of which 579 corresponded to the -subunit-coding region (Urban et al. 1994) . To check for possible differences in quantification and/or loading, samples were also assayed for 18S RNA using human 18S cDNA (pT7 RNA 18S) obtained from Ambion (Austin, TX, USA). To obtain a low specific activity probe, the linearized plasmid was transcribed using the RiboMAX large scale RNA production system using T7 polymerase (Promega). The 18S RNA probe consisted of 116 nucleotides and protected an RNA doublet of 80 and 70 bp.
Solution hybridization-RNase protection assays were conducted for GHR and IGF-IR mRNA respectively as follows: 20 µg total RNA were incubated with 300 000 c.p.m. [ 32 P]RNA probe in the presence or absence of 32 P-labelled 18S RNA probe (20 000 c.p.m., 1 µg) overnight at 45 C in 29 µl hybridization buffer (20 m Tris-HCl, pH 7·5, 1 m EDTA, 0·4 m NaCl, 0·1% SDS, 75% formamide). The unhybridized strands were digested with RNases A and T1 (RNase Cocktail; Ambion) for 45 min at 37 C. Digestion by RNases was followed by incubation with Proteinase K (Eurobio, Les Ulis, France), phenol-chloroform extraction, and ethanol precipitation of hybridized specific GHR or IGF-IR mRNA. Samples and a [ 32 P]DNA size marker were then resuspended in gel dye and separated by size on 6% polyacrylamide/6  urea gels. Radioactive bands were visualized by autoradiography of dried gels using X-OMAT XAR film (Kodak, Rochester, NY, USA) and double intensifying screens for 1-3 days at 70 C. A single band was observed for GHR mRNA while two bands with similar relative intensities were observed for IGF-IR mRNA. Unhybridized probes digested or undigested by RNases were used as control. The relative intensities of the protected bands were quantified using Densylab software (Microvision Instruments, Evry, France). The data were not normalized to the abundance of 18S RNA. However, when the 18S RNA was barely detectable, the value of GHR was not considered.
Statistical analysis
All data are expressed as means ... Data were processed by ANOVA using the General Linear Model procedure of SAS (1989) . The model included the main effect of treatment and litter.
Results
IGF-I and GHBP levels in plasma
Plasma IGF-I concentrations were 3·3 times higher in pGH-treated than in control pigs (P<0·001) ( Table 1) . I-Labelled hGH-specific binding in plasma was similar in pGH-treated and control pigs (Table 1) .
GHR levels in liver and skeletal muscle
Administration of pGH increased 125 I-labelled bGHspecific binding in liver (P<0·05) but had no effect in LD and TR muscles (Fig. 1) . GH treatment increased GHR mRNA levels in liver (P<0·05) and depressed them in LD (P<0·05), while no significant effect was observed in TR muscle (Figs 2 and 3) .
IGF-IR levels in liver and skeletal muscle
In liver, 125 I-labelled IGF-I specific binding was not affected by GH treatment (Fig. 4) . As previously described in pigs, levels of 125 I-labelled IGF-I-specific binding to skeletal muscle were very low at 180 days of age and therefore no effect of GH treatment could be observed (data not shown). IGF-IR mRNA abundance was not significantly influenced by GH treatment in any of the three tissues examined (Figs 2 and 5) .
Discussion
The present study is the first to assess the effect of GH administration on both GHR and IGF-IR levels in skeletal muscle. The effects of GH on hepatic receptor levels and on plasma GHBP and IGF-I levels have been examined in parallel. The finding that plasma IGF-I concentrations were 3·3-fold higher in pGH-treated than in control pigs is in accordance with previous studies (Chung & Etherton 1986 , Grant et al. 1991 , Coleman et al. 1994 and indicates that treated pigs significantly responded to GH treatment.
As previously described in rat (Baxter & Zaltsman 1984) , sheep (Bass et al. 1991) and pig (Chung & Etherton 1986 , Ambler et al. 1992 , GH treatment induced an increase in GH binding to liver. The influence of GH treatment on GHR mRNA levels has been studied less extensively. In accordance with a recent finding (Brameld et al. 1996) , the present work indicates that GH administration increased GHR mRNA levels in liver. In contrast, it has been shown in the rat that GH treatment does not affect hepatic GHR mRNA levels in either hypophysectomized (Mathews et al. 1989 , Maiter et al. 1992 , Domene et al. 1993 or intact animals (Ohashi et al. 1995 ). The present study, which examines for the first time both GH binding and GHR mRNA levels, suggests that regulation of GHR may take place at the transcriptional level in the pig.
Although GH administration is known to increase muscle mass in pigs (Chung et al. 1985 , Campbell et al. 1989 , it is not known whether this effect is associated with a change in GH-binding level in that tissue. The present experiment shows that there was no effect of GH administration on GH binding in LD and TR muscles. The finding that GH did not affect mRNA level in TR and decreased it in LD muscle is not consistent with a recent study in pigs showing that GH increased mRNA level in LD and semitendinosus muscles (Brameld et al. 1996) . The discrepancy between the two studies could be related to differences in experimental conditions (GH dose, treatment duration or age of the animals). The importance of age has been reported previously. Indeed, it has been observed that the GH-induced increase in GH binding to liver is much higher in 30-day-old pigs (81%) than in 120-day-old pigs (15%) (Ambler et al. 1992) . The finding of an increase in hepatic GHR levels with no change in GHR levels in muscle indicates that GH treatment affects GHR levels in a tissue-specific manner. Such a tissue-specific regulation of GHR has been previously shown in several situations, including development (Brameld et al. 1995 , Schnoebelen-Combes et al. 1996 , food restriction (Dauncey et al. 1994) and hypophysectomy (Frick et al. 1990) .
In the present experiment, the lack of effect of GH treatment on plasma GHBP level contrasts with the finding of a GH-induced increase in plasma GHBP level in infant and pubertal pigs (Ambler et al. 1992) . It was also observed in the same study that, whereas longterm pGH treatment slightly increased plasma GHBP level, short-term pGH treatment did not affect it (Mullins & Davis 1992) . In GH-deficient children, GH treatment restored plasma GHBP level to that of normal children (Postel-Vinay et al. 1991) , while in patients with Turner's syndrome with relatively high plasma GHBP level, GH treatment did not up-regulate it (Massa et al. 1992) . Taken together, these data indicate that the effect of GH on plasma GHBP is still not clear. Further studies are needed to determine factors regulating plasma GHBP in response to GH treatment.
As GHBP might be derived from GHR by enzymic cleavage in pigs, as in humans and rabbits (Leung et al. 1987) , plasma GHBP levels might reflect GHR levels in tissues. Because liver is considered to be the main GH target tissue, the relationship between plasma GHBP and hepatic GHR was evaluated in most of the studies performed so far. Our study failed to show any relationship between plasma GHBP and GHR level in liver. This finding agrees with the study of Ambler et al. (1992) , who observed a positive correlation between plasma GHBP level and GH binding to liver after GH administration in infant but not pubertal pigs. Together, these data indicate that there is no simple relationship between plasma GHBP and hepatic GHR, but they do not exclude the hypothesis that plasma GHBP may be a good indicator of total GHR status. The lack of parallelism between these two parameters may be related to the presence of GHR in other tissues such as skeletal muscle (Schnoebelen-Combes et al. 1996) and to the tissue-specific regulation of GHR. Thus further studies are needed to identify the tissues generating GHBP and the mechanism(s) regulating GHBP generation.
The lack of effect of GH on IGF-IR in liver and skeletal muscle is consistent with recent results which indicate that IGF-IR was not affected by a GH deficiency in rat (Butler et al. 1996) . The absence of any modification of IGF-IR level despite an increase in plasma IGF-I concentrations contrasts with in vitro studies which demonstrate that IGF-I down-regulates its own receptor (Rosenfeld & Dollar 1982 , Rosenthal et al. 1991 . The IGF-I downregulation of its own receptor demonstrated in vitro may not be clearly expressed in vivo. Indeed, the GH-induced increase in plasma IGF-I concentration could not further decrease the IGF-IR level, which is very low in 180-dayold pigs . Whether GH treatment could decrease IGF-IR in younger pigs remains to be investigated.
GH plays an important role in promoting growth. Many of the somatogenic effects of GH are believed to be mediated by IGF-I produced by the liver or locally synthesized (D'Ercole et al. 1984 , Froesch et al. 1985 . In the rat, the finding that GH regulates the level of IGF-I mRNA in skeletal muscle (Isgaard et al. 1989 , Butler et al. 1996 supports the hypothesis that skeletal muscle growth may be mediated by locally produced IGF-I. However, the finding that GH administration did not affect GHR and IGF-IR levels associated with previous observations demonstrating that GH treatment did not change IGF-I mRNA levels in porcine skeletal muscle (Grant et al. 1991 , Coleman et al. 1994 does not allow us to draw any conclusion on the mechanism by which GH administration affects muscle growth in the pig. Therefore whether GH acts directly on muscle through its own receptor and/or through circulating or locally IGF-I remains to be determined.
In conclusion, the present study shows for the first time that GH binding and IGF-IR mRNA in pig skeletal muscle are not affected by GH administration. Although the stimulatory effect of GH on pig muscle growth is well known, further studies are needed to elucidate the mechanism involved in GH action. Our results also indicate that GH regulation of GHR is tissue-specific and that hepatic GHR and plasma GHBP are not co-regulated in pGH-treated pigs.
